916811-87-5

Basic information

• Product Name: 7-BROMO-2-(4-MORPHOLINYL)QUINOXALINE
• Synonyms: 7-BROMO-2-(4-MORPHOLINYL)QUINOXALINE;4-(7-Bromoquinoxalin-2-yl)morpholine
• CAS NO: 916811-87-5
• Molecular Formula: C₁₂H₁₂BrN₃O
• Molecular Weight: 294.15
• Mol File: 916811-87-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 445.126°C at 760 mmHg
• Flash Point: 223.005°C
• Appearance: /
• Density: 1.552g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.658
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-BROMO-2-(4-MORPHOLINYL)QUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-2-(4-MORPHOLINYL)QUINOXALINE(916811-87-5)
• EPA Substance Registry System: 7-BROMO-2-(4-MORPHOLINYL)QUINOXALINE(916811-87-5)

Safety Data

• Hazardous Substances Data: 916811-87-5(Hazardous Substances Data)

Usage

Description

7-Bromo-2-(4-morpholinyl)quinoxaline, a quinoxaline derivative with the molecular formula C12H9BrN2O, is a chemical compound featuring a bromine atom and a morpholine group attached to the quinoxaline ring. It is recognized for its diverse biological activities and serves as a valuable building block in pharmaceutical research and development, particularly for the synthesis of potential drug candidates. Its unique structure and promising biological and pharmacological properties have attracted significant interest in the scientific community.

Uses

Used in Pharmaceutical Research and Development:
7-Bromo-2-(4-morpholinyl)quinoxaline is utilized as a key intermediate in the synthesis of potential drug candidates due to its unique structure and biological activities. It aids in the development of novel chemical entities with therapeutic applications.
Used as an Enzyme and Receptor Inhibitor:
In the field of medicinal chemistry, 7-bromo-2-(4-morpholinyl)quinoxaline is employed as an inhibitor of certain enzymes and receptors, playing a crucial role in modulating biological processes and pathways related to various diseases.
Used in the Synthesis of Novel Chemical Entities:
7-Bromo-2-(4-morpholinyl)quinoxaline is used as a versatile building block for the creation of new chemical entities with potential therapeutic applications, contributing to the advancement of drug discovery and development.

InChI:InChI=1/C12H12BrN3O/c13-9-1-2-10-11(7-9)15-12(8-14-10)16-3-5-17-6-4-16/h1-2,7-8H,3-6H2

Upstream product

• 1196-57-2 2-hydroxyquinoxaline 
• 82031-32-1 2-hydroxy-7-bromoquinoxaline 
• 89891-65-6 7-bromo-2-chloroquinoxaline 
• 110-91-8 morpholine 
• 2251-59-4 7-bromo-2-fluoroquinoxaline 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 
• 82031-32-1 7-bromo-1H-quinoxalin-2-one 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 1271847-02-9 4-(3-morpholin-4-yl-quinoxalin-6-yl)-phenylamine 
• 1271829-25-4 7-(2-methoxy-phenyl)-2-morpholin-4-yl-quinoxaline 
• 1609932-19-5 1-(4-(3-morpholinoquinoxaline-6-carbonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1609932-62-8 (4-aminophenyl)(3-morpholinoquinoxalin-6-yl)methanone 
• 1609932-61-7 N-(4-(3-morpholinoquinoxaline-6-carbonyl)phenyl)pivalamide 
• 1609932-60-6 N-(4-(hydroxy(3-morpholinoquinoxalin-6-yl)methyl)phenyl)pivalamide 
• 1427632-35-6 1-(3-fluorophenyl)-3-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)urea 
• 1427633-05-3 N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)-3-(trifluoromethyl)benzamide 
• 1425485-87-5 C₂₂H₂₁F₃N₄O₄S 
• 1425486-33-4 N-(propylsulfonyl)-N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide 
• 1425486-32-3 (3-amino-2,5,6-trifluorophenyl)(3-morpholinoquinoxalin-6-yl)methanone 
• 1425486-31-2 N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)pivalamide 
• 1425486-30-1 N-(2,4,5-trifluoro-3-(hydroxy(3-morpholinoquinoxalin-6-yl)methyl)phenyl)pivalamide 
• 1201842-02-5 N-(2-chloro-5-(3-morpholinoquinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 

Relevant articles and documents

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

Nowadays, the simultaneous inhibition of two or more pathways plays an increasingly important role in cancer treatment due to the complex and diverse pathogenesis of cancer, and the combination of the cyclin-dependent kinase 6 (CDK6) inhibitor and PIM1 inhibitor was found to generate synergistic effects in acute myeloid leukemia (AML) treatment. Therefore, we discovered a novel lead 1 targeting CDK6/PIM1 via pharmacophore-based and structure-based virtual screening, synthesized five different series of new derivates, and obtained a potent and balanced dual CDK6/PIM1 inhibitor 51, which showed high kinase selectivity. Meanwhile, 51 displayed an excellent safety profile and great pharmacokinetic properties. Furthermore, 51 displayed stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo. In summary, we offered a new direction for AML treatment and provided a great lead compound for AML preclinical studies.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.